Go Pro
NASDAQ:VVOS

Vivos Therapeutics Q1 2026 Earnings Report

Vivos Therapeutics logo
$0.45 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$0.46 +0.00 (+1.06%)
As of 07/2/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vivos Therapeutics EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.45
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Vivos Therapeutics Revenue Results

Actual Revenue
$5.14 million
Expected Revenue
$4.35 million
Beat/Miss
Beat by +$792.00 thousand
YoY Revenue Growth
N/A

Vivos Therapeutics Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Wednesday, May 20, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Vivos Therapeutics' Q2 2026 earnings is estimated for Tuesday, August 18, 2026, based on past reporting schedules, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Vivos Therapeutics Earnings Headlines

Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel
See More Vivos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivos Therapeutics and other key companies, straight to your email.

About Vivos Therapeutics

Vivos Therapeutics (NASDAQ:VVOS) is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol. Clinicians are guided through patient assessment, imaging and diagnostic procedures, appliance design and fitting, and ongoing monitoring. In addition to device manufacturing, Vivos Therapeutics provides comprehensive training and certification programs for dental professionals, enabling a standardized approach to screening, treatment planning, and patient follow-up within the Vivos network.

Headquartered in Lone Tree, Colorado, Vivos Therapeutics markets its solutions through a network of licensed dental practitioners across the United States and select international regions, including Canada, Europe and parts of Asia-Pacific. The company continues to expand its footprint by partnering with accredited educational institutions and professional societies to promote awareness of oral appliance therapy as a first-line intervention for airway health.

View Vivos Therapeutics Profile